Sort   by:  
 Page size 
MetabolomicsSPE-IMS-MS: An automated platform for sub-sixty second surveillance of endogenous metabolites and xenobiotics in biofluids
Characterization of endogenous metabolites and xenobiotics is essential to deconvoluting the genetic and environmental causes of disease. However, surveillance of chemical exposure and disease-related changes in large cohorts requires an analytical platform that offers rapid measurement, high sensit...
2017-02-14 | MTBLS427 | MetaboLights
ProteomicsPeptide standard acquired with the dual-gated SLIM-Orbitrap
Raw data collected on the dual-gated SLIM-Orbitrap. The sample contained a mixture of standard peptides at 1 uM equimolar concentration in 60:40 water:acetonitrile with 1% acetic acid (v/v). The peptides were kemptide, angiotensin I, bradykinin, neurotensin, angiotensin II, renin substrate tetradeca...
ORGANISM(S): Peptide Standards 
2023-08-23 | MSV000092738 | MassIVE
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Not available
S-EPMC9271031 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
UnknownGlobal, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Not available
S-EPMC6227755 | biostudies-literature
UnknownNew-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry.
Not available
S-EPMC10834159 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
Sort   by:  
 Page size